Methotrexate Tapering in Rheumatoid Arthritis

Prerequisites and Tapering Sequence

The European League Against Rheumatism recommends that methotrexate tapering should only be considered after patients achieve persistent remission or low disease activity for at least 6 months, and only after first tapering glucocorticoids and biologics if present 1, 2, 3
The American College of Rheumatology suggests that disease activity must be in sustained remission or low disease activity for a minimum of 6 months before considering methotrexate dose reduction 1, 2, 3
All glucocorticoids must be tapered first and discontinued before tapering methotrexate, as recommended by the European League Against Rheumatism 1, 2
Biologic or targeted synthetic DMARDs should be tapered before conventional synthetic DMARDs like methotrexate, according to the American College of Rheumatology 1, 2

The recommended approach is to reduce methotrexate dose by 50% initially rather than stopping completely, and to monitor disease activity every 1-3 months during the tapering process, as suggested by the European League Against Rheumatism 1, 2, 3
If disease activity increases, immediately return to the previous effective dose, as recommended by the American College of Rheumatology 3, 4
Assess disease activity every 1-3 months using validated measures (DAS28, SDAI, or CDAI), as suggested by the European League Against Rheumatism 1, 2, 3

Methotrexate tapering should not be attempted in patients with remission duration less than 6 months, patients still requiring glucocorticoids to maintain disease control, patients with progressive subcutaneous nodules, or patients with high disease activity or poor prognostic factors, as recommended by the American College of Rheumatology 1, 2, 3
The decision to taper must be made through shared decision-making with the patient, clearly explaining that maintaining full-dose therapy provides the lowest risk of flare, as suggested by the European League Against Rheumatism 3, 4

Patients with seronegative rheumatoid arthritis must be in persistent low disease activity or remission for at least 6 months before considering any tapering strategy, as recommended by the American College of Rheumatology 5, 6
Disease activity should be measured using validated instruments such as DAS28 or SDAI to confirm stable disease control, with a strength of evidence based on high-quality studies 6

If the patient is on glucocorticoids, these should be tapered first before considering DMARD tapering, according to the European League Against Rheumatism 7
Glucocorticoids should be tapered as rapidly as clinically feasible to minimize long-term adverse effects, with a moderate strength of evidence 8

Disease activity should be monitored frequently during tapering (every 1-3 months), with a high strength of evidence for this approach 9, 7
Tapering should be implemented as a shared decision between patient and physician, with clear discussion of potential benefits and risks, as recommended by the American College of Rheumatology 10
Conventional synthetic DMARDs should be tapered only after successful tapering of biologics and with continued remission, according to the European League Against Rheumatism 7

The presence of radiographic damage should be considered when making tapering decisions, with a moderate strength of evidence for this consideration 11
Seronegative status itself is not specifically addressed in guidelines for tapering, so standard RA tapering principles apply, as recommended by the American College of Rheumatology 5, 9